A practical reference on LC-MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-15 and is reviewed periodically as new material appears.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Common matrix | Plasma or serum | Collected under controlled conditions |
| Primary method | Liquid chromatography–tandem mass spectrometry | Structural specificity |
| Alternative method | Immunoassay | Lower specificity, higher throughput |
| Reporting unit | ng/mL | Concentration in matrix |
| Key validation item | Selectivity | Interference from related peptides |
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
== History == Obsidian hydration dating was introduced in 1960 by Irving Friedman and Robert Smith of the U.S. Geological Survey. Their initial work focused on obsidians from archaeological sites in western North America. The use of Secondary ion mass spectrometry (SIMS) in the measurement of obsidian hydration dating was introduced by two independent research teams in 2002. Today the technique is applied extensively by archaeologists to date prehistoric sites and sites from prehistory in California and the Great Basin of North America. It has also been applied in South America, the Middle East, the Pacific Islands, including New Zealand and Mediterranean Basin.
=== Constituents === Nutmeg consists of 25 to 40% fatty oils or triglycerides (nutmeg butter), 7 to 16% volatile oils, and 45 to 60% pulp or structural components like cellulose. The triglyceride part is mostly trimyristin, but triolein and trilinolein are also found in small amounts. The psychoactive component of nutmeg appears to be the volatile oil component, with most of the rest inactive in animals and humans. It consists 80% of a terpene fraction, 10 to 15% of an aromatic fraction, and the small remainder fatty acids. Turpentine, a fluid made from the resin mainly of pine trees, has a similar composition as the terpene fraction of nutmeg, but has no reputation for producing intoxicating effects. The aromatic fraction of nutmeg consists of a number of allylbenzenes (propenylbenzenes), mainly myristicin, elemicin, and safrole (these three 84–95%), but also including methyleugenol, methylisoeugenol, methoxyeugenol, isoeugenol, eugenol, and isoelemicin. A 20 gram amount of nutmeg contains about 210 mg myristicin, 70 elemicin, 39 mg safrole, as well as 3 to 18 mg each of the other compounds. Myristicin makes up approximately 1.3% of whole nutmeg and about 4 to 13% of the volatile oil fraction. Myristicin and elemicin have been thought to be nutmeg's psychoactive constituents, whereas safrole and the various eugenols seem to be inactive with regard to such effects. Though other nutmeg components are inactive, they might aid in the absorption of the active constituents.
Strontium is a divalent silvery metal with a pale yellow tint whose properties are mostly intermediate between and similar to those of its group neighbors calcium and barium. It is softer than calcium and harder than barium. Its melting (777 °C) and boiling (1377 °C) points are lower than those of calcium (842 °C and 1484 °C respectively); barium continues this downward trend in the melting point (727 °C), but not in the boiling point (1900 °C). The density of strontium (2.64 g/cm3) is similarly intermediate between those of calcium (1.54 g/cm3) and barium (3.594 g/cm3). Three allotropes of metallic strontium exist, with transition points at 235 and 540 °C. The standard electrode potential for the Sr(2+)/Sr couple is −2.89 V, approximately midway between those of the Ca(2+)/Ca (−2.84 V) and Ba(2+)/Ba (−2.92 V) couples, and close to those of the neighboring alkali metals. Strontium is intermediate between calcium and barium in its reactivity toward water, with which it reacts on contact to produce strontium hydroxide and hydrogen gas. Strontium metal burns in air to produce both strontium oxide and strontium nitride, but since it does not react with nitrogen below 380 °C, at room temperature it forms only the oxide spontaneously. Besides the simple oxide SrO, the peroxide SrO2 can be made by direct oxidation of strontium metal under a high pressure of oxygen, and there is some evidence for a yellow superoxide Sr(O2)2. Strontium hydroxide, Sr(OH)2, is a strong base, though it is not as strong as the hydroxides of barium or the alkali metals.
Mast cells use a variety of cell surface receptors to detect pathogens. The best known pathway involves FcεRI, a high-affinity receptor for the Fc region of IgE antibodies, involved in allergies. As a molecular target, FcεRI initiates various outcomes in mast cells (MCs) in response to antigens (Ags). Ags bind to immunoglobulin E (IgE) that is bound to FcεRI to cause the crosslinking of IgE–FcεRI complexes and trigger mast cell activation. Activation leads within minutes to degranulation of mast cells and the release of mediators such as histamine, serotonin, and leukotrienes, followed over a period of hours by the secretion of cytokines, chemokines, and growth factors. FcεRI regulates the Ag–IgE interaction, driving allergic responses. FcεRI clustering controls signal transduction and the quality of MC responses. Under resting conditions in the cell membrane, the IgE–FcεRI complex diffuses freely. Multivalent Ag binding to IgE reorganizes FcεRI within seconds to minutes, forming large aggregates on the cell surface, and causing a transition in the receptor from a diffuse to an immobile state. Small aggregates remain mobile on the cell surface, whereas large aggregates abruptly become immobile. Changes in the mobility, kinetics, and size of FcεRI clusters may govern signal initiation and termination. In addition to IgE-dependent MC activation, forms of IgE-independent MC activation have been studied. One of these involves MRGPRX2, a G protein-coupled receptor (GPCR).
Sources: en.wikipedia.org
In 2001, Otto Reich, a hardline Republican Anti-Castro Cuban-born exile in the United States, who had formerly been involved in the Iran–Contra affair, was at the time the Assistant Secretary of State for Western Hemisphere Affairs. He approached Marc Wachtenheim from the Pan American Development Foundation, a subcontractor for the United States Agency for International Development (USAID), to hatch a development program to reopen Cuba, and then developed a covert influence campaign that might lead to conditions that could foment revolution there. They decided that because Freemasonry had been so present in Cuban society, to cultivate the Grand Lodge of Cuba. In 2001, Marc Wachtenheim brought Grand Master Collera Venta to Washington, D.C. to meet with Otto Reich. The staff of the United States Interests Section in Havana were well aware of the fact that Grand Master Collera Venta was a Cuban counterintelligence officer at the State Security Unit (DSE) (Spanish: Departamento de Seguridad del Estado) who went by the codename Agente Gerardo, and had been a spy for over 25 years. They did not share this information with USAID, nor any of their subcontractors, because the subcontractors didn't share their own plans with the Interests Section. The greater staff of the US diplomatic mission in Havana were aware of Collera Venta's true employment by 2007 – but they still did not inform USAID. Collera Venta later told CNN: "My job was to discover and neutralize these plans against my country."
===== Junior residency (Part I) ===== Duration: 24 to 36 months. Objective: Develop core clinical competencies and foundational knowledge in the chosen specialty. Assessment: Candidates are eligible to sit for the Part I Fellowship Examination after completing this phase.
=== 1. Ideality === In June 2010, Baran authored a paper describing the "Ideal Synthesis" in which he presents a simple and informative definition of "ideality" when comparing molecular syntheses. Building off of ideas discussed by James B. Hendrickson in 1975, "ideality" refers to the concept of making molecules in a way that minimizes concession steps (e.g. adding/removing protecting groups) and maximizes construction steps (i.e. C-C or C-heteroatom bond forming and strategic redox steps). Importantly, this conversation of synthetic ideality is limited to comparisons of syntheses of the same molecule.
Sources: en.wikipedia.org
Tzaraath, a Biblical disease that disfigures the skin, is often identified as leprosy, and may be the source of many myths about the disease. Rust itself does not cause tetanus infection. The bacterium that causes tetanus thrives in low oxygen environments, including rust where the oxygen has combined with iron, so many people associate rust with tetanus. However, any puncture wound can introduce spores that cause a tetanus infection, not just rusty nails. Quarantine has never been a standard procedure for those with severe combined immunodeficiency, despite the condition's popular nickname ("bubble boy syndrome") and its portrayal in films. A bone marrow transplant in the earliest months of life is the standard course of treatment. The exceptional case of David Vetter, who lived much of his life encased in a sterile environment because he would not receive a transplant until age 12, was an inspiration for the "bubble boy" trope. Post-exposure prophylaxis for rabies does not require a painful series of injections into the abdomen with a long needle. Prior to the 1980s, the rabies vaccine did indeed require injection into the abdomen, but modern rabies vaccines are given as intramuscular injections into the deltoid muscle of the upper arm. Statements in medication package inserts listing the frequency of side effects describe how often the effect occurs after taking a drug, but are not making any assertion that there is a causal connection between taking the drug and the occurrence of the side effect.
Connective tissue in skeletal muscle Dorsal artery of the penis (example of integument enclosing an internal organ) Flensing Flesh (generic use of plural "integuments") Herzog & de Meuron (figurative usage) Integumentary system (senses related to vertebrate skin and medical aspects) Integumental muscles Mosasaur Seed
== Non-Proton (1H) MRS == 31Phosphorus Magnetic Resonance Spectroscopy 1H MRS's clinical success is only rivaled by 31P MRS. This is in large part because of the relatively high sensitivity of phosphorus NMR (7% of protons) combined with a 100% natural abundance. Consequently, high-quality spectra are acquired within minutes. Even at low field strengths, great spectra resolution is obtained because of the relatively large (~30 ppm) chemical shift dispersion for in vivo phosphates. Clinically, phosphorus NMR excels because it detects all metabolites playing key roles in tissue energy metabolism and can indirectly deduce intracellular pH. However, phosphorus NMR is chiefly challenged by the limited number of metabolites it can detect. 13Carbon Magnetic Resonance Spectroscopy In contrast to phosphorus NMR, carbon NMR is an insensitive technique. This arises from the fact that 13C NMR has a low abundance (1.1%) and carbon's low gyromagnetic ratio. This low abundance is because 12C does not have a magnetic moment, making it not NMR active, leading to 13C's use for spectroscopy purposes. However, this low sensitivity can be improved via decoupling, averaging, polarization transfer, and larger volumes. Despite the low natural abundance and sensitivity of 13C, 13C MRS has been used to study several metabolites, especially glycogen and triglycerides. It has proven especially useful at providing insight on the metabolic fluxes from 13C-labeled precursors.
Sources: en.wikipedia.org
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.
Mass spectrometry identifies molecules by mass-to-charge transitions, which reduces interference from related peptides. Immunoassays run faster but can cross-react. Structural confirmation usually requires the mass spectrometric approach.
Cardiovascular outcomes, long-term safety, and weight regain after stopping treatment are unresolved. These questions need years of follow-up data. Published evidence covers only limited treatment durations.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.